Ordinance
on Clinical Trials
with the exception of
Clinical Trials of Medical Devices1
(Clinical Trials Ordinance, ClinO)

of 20 September 2013 (Status as of 26 May 2022)

1 Amended by Annex 2 No 2 of the O of 1 July 2020 on Clinical Trials with Medical Devices, in force since 26 May 2021 (AS 2020 3033).


Open article in different language:  DE  |  FR  |  IT
Art. 45 Data retention requirements

1 The spon­sor must re­tain all data re­lat­ing to the clin­ic­al tri­al un­til the ex­piry date of the last batch sup­plied of the medi­cin­al product un­der in­vest­ig­a­tion or of the last product un­der Art­icle 2a para­graph 2 TPA man­u­fac­tured, but at least for ten years after the com­ple­tion or dis­con­tinu­ation of the clin­ic­al tri­al. In the case of products un­der Art­icle 2a para­graph 2 TPA that can be im­planted, the re­ten­tion peri­od amounts to a min­im­um of 15 years.41

2 The in­vest­ig­at­or must re­tain all doc­u­ments re­quired for the iden­ti­fic­a­tion and fol­low-up of par­ti­cipants, and all oth­er ori­gin­al data, for at least ten years after the com­ple­tion or dis­con­tinu­ation of the clin­ic­al tri­al. In the case of products un­der Art­icle 2a para­graph 2 TPA that can be im­planted, the re­ten­tion peri­od amounts to a min­im­um of 15 years.42

3 For clin­ic­al tri­als of trans­plant products and for clin­ic­al tri­als of blood and blood products, the re­ten­tion re­quire­ments are gov­erned by Art­icle 40 para­graph 1 TPA.

41 Amended by An­nex 2 No 2 of the O of 4 May 2022, in force since 26 May 2022 (AS 2022 294).

42 Amended by An­nex 2 No 2 of the O of 4 May 2022, in force since 26 May 2022 (AS 2022 294).

Diese Seite ist durch reCAPTCHA geschützt und die Google Datenschutzrichtlinie und Nutzungsbedingungen gelten.

Feedback
Laden